← MiniMed Group, Inc. Common Stock overview

MiniMed Group, Inc. Common Stock vs The Cooper Companies: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

MiniMed Group, Inc. Common Stock (MMED)

Q3 2026
▲3

MiniMed Flex Launch Drives Strong Q1, Raised Outlook

  • MiniMed Flex pump launch MiniMed launched its smallest app-controlled insulin pump in the U.S. in June, with a new sensor and algorithm. The Flex drove new pump sales up over 20% and new prescribers up 24%, powering U.S. revenue growth to 13.1% from 1.5%.

    The Flex launch is the core new product driving MiniMed's accelerating growth and is the main reason the stock is moving.

  • Abbott sensor partnership expands Abbott began supplying its Instinct sensor for MiniMed's new pump in August, and the FDA approved Abbott's dual ketone-glucose monitor with an exclusive MiniMed integration for smart dosing. This broadens MiniMed's sensor options and strengthens its product ecosystem.

    The Abbott partnership is a new collaboration that enhances MiniMed's competitive position and future product pipeline.

  • Strong Q1 results and raised guidance MiniMed reported Q1 revenue of $843 million, up 15.8% organically, and raised full-year organic growth guidance to about 10.5%. The company narrowed its net loss to zero and reaffirmed its 16% adjusted EBITDA margin target, boosting investor confidence.

    The earnings beat and guidance raise are the key financial catalysts that directly lifted the stock price.

  • Profitability lags and hedge fund conviction weakens Despite strong revenue, adjusted EBITDA margin was only 9.9% and free cash flow was negative $90 million due to separation costs. Hedge fund holdings fell 18% in Q2, and short interest stands at 20.66% of float, signaling some caution.

    This is the main counterweight: profitability and cash flow are not yet keeping pace with revenue growth, and some investors are pulling back.

July 2026
▲3

MiniMed Flex Launch Drives Strong Q1, Raised Outlook

  • MiniMed Flex pump launch MiniMed launched its smallest app-controlled insulin pump in the U.S. in June, with a new sensor and algorithm. The Flex drove new pump sales up over 20% and new prescribers up 24%, powering U.S. revenue growth to 13.1% from 1.5%.

    The Flex launch is the core new product driving MiniMed's accelerating growth and is the main reason the stock is moving.

  • Abbott sensor partnership expands Abbott began supplying its Instinct sensor for MiniMed's new pump in August, and the FDA approved Abbott's dual ketone-glucose monitor with an exclusive MiniMed integration for smart dosing. This broadens MiniMed's sensor options and strengthens its product ecosystem.

    The Abbott partnership is a new collaboration that enhances MiniMed's competitive position and future product pipeline.

  • Strong Q1 results and raised guidance MiniMed reported Q1 revenue of $843 million, up 15.8% organically, and raised full-year organic growth guidance to about 10.5%. The company narrowed its net loss to zero and reaffirmed its 16% adjusted EBITDA margin target, boosting investor confidence.

    The earnings beat and guidance raise are the key financial catalysts that directly lifted the stock price.

  • Profitability lags and hedge fund conviction weakens Despite strong revenue, adjusted EBITDA margin was only 9.9% and free cash flow was negative $90 million due to separation costs. Hedge fund holdings fell 18% in Q2, and short interest stands at 20.66% of float, signaling some caution.

    This is the main counterweight: profitability and cash flow are not yet keeping pace with revenue growth, and some investors are pulling back.

Latest
▲3

MiniMed Flex Launch Drives Strong Q1, Raised Outlook

  • MiniMed Flex pump launch MiniMed launched its smallest app-controlled insulin pump in the U.S. in June, with a new sensor and algorithm. The Flex drove new pump sales up over 20% and new prescribers up 24%, powering U.S. revenue growth to 13.1% from 1.5%.

    The Flex launch is the core new product driving MiniMed's accelerating growth and is the main reason the stock is moving.

  • Abbott sensor partnership expands Abbott began supplying its Instinct sensor for MiniMed's new pump in August, and the FDA approved Abbott's dual ketone-glucose monitor with an exclusive MiniMed integration for smart dosing. This broadens MiniMed's sensor options and strengthens its product ecosystem.

    The Abbott partnership is a new collaboration that enhances MiniMed's competitive position and future product pipeline.

  • Strong Q1 results and raised guidance MiniMed reported Q1 revenue of $843 million, up 15.8% organically, and raised full-year organic growth guidance to about 10.5%. The company narrowed its net loss to zero and reaffirmed its 16% adjusted EBITDA margin target, boosting investor confidence.

    The earnings beat and guidance raise are the key financial catalysts that directly lifted the stock price.

  • Profitability lags and hedge fund conviction weakens Despite strong revenue, adjusted EBITDA margin was only 9.9% and free cash flow was negative $90 million due to separation costs. Hedge fund holdings fell 18% in Q2, and short interest stands at 20.66% of float, signaling some caution.

    This is the main counterweight: profitability and cash flow are not yet keeping pace with revenue growth, and some investors are pulling back.

The Cooper Companies, Inc (COO)

Q3 2026
▲2▼1

Cooper cuts guidance, keeps CooperSurgical; activist Jana pushes for sale

  • Guidance cut and strategic review ends with CooperSurgical retained Cooper cut its fiscal 2026 revenue and profit outlook below what analysts expected and decided to keep its women's health unit, CooperSurgical, instead of selling it. The weak forecast and no-sale decision sent the stock down sharply, because investors had hoped a sale would unlock value.

    This is the main new event that drove the stock down this period.

  • Buyback expanded to $3 billion Alongside the weak guidance, Cooper increased its share buyback program from $2 billion to $3 billion, leaving about $1.5 billion available. Buying back more stock can support the share price by reducing the number of shares outstanding, but it did not offset the negative reaction to the guidance cut.

    This is a new capital action that partially offsets the negative guidance news.

  • Activist Jana Partners pushes for sale and CEO change Activist investor Jana Partners sent a letter urging Cooper to pursue a sale, replace its CEO, and consider selling assets. The stock rose 1.7% after hours on the news, as investors saw a chance for a shake-up that could boost value after a 34% year-to-date decline.

    This is the latest new development that could change the company's direction and stock price.

September 2026
▲2▼1

Cooper cuts guidance, keeps CooperSurgical; activist Jana pushes for sale

  • Guidance cut and strategic review ends with CooperSurgical retained Cooper cut its fiscal 2026 revenue and profit outlook below what analysts expected and decided to keep its women's health unit, CooperSurgical, instead of selling it. The weak forecast and no-sale decision sent the stock down sharply, because investors had hoped a sale would unlock value.

    This is the main new event that drove the stock down this period.

  • Buyback expanded to $3 billion Alongside the weak guidance, Cooper increased its share buyback program from $2 billion to $3 billion, leaving about $1.5 billion available. Buying back more stock can support the share price by reducing the number of shares outstanding, but it did not offset the negative reaction to the guidance cut.

    This is a new capital action that partially offsets the negative guidance news.

  • Activist Jana Partners pushes for sale and CEO change Activist investor Jana Partners sent a letter urging Cooper to pursue a sale, replace its CEO, and consider selling assets. The stock rose 1.7% after hours on the news, as investors saw a chance for a shake-up that could boost value after a 34% year-to-date decline.

    This is the latest new development that could change the company's direction and stock price.

Latest
▲2▼1

Cooper cuts guidance, keeps CooperSurgical; activist Jana pushes for sale

  • Guidance cut and strategic review ends with CooperSurgical retained Cooper cut its fiscal 2026 revenue and profit outlook below what analysts expected and decided to keep its women's health unit, CooperSurgical, instead of selling it. The weak forecast and no-sale decision sent the stock down sharply, because investors had hoped a sale would unlock value.

    This is the main new event that drove the stock down this period.

  • Buyback expanded to $3 billion Alongside the weak guidance, Cooper increased its share buyback program from $2 billion to $3 billion, leaving about $1.5 billion available. Buying back more stock can support the share price by reducing the number of shares outstanding, but it did not offset the negative reaction to the guidance cut.

    This is a new capital action that partially offsets the negative guidance news.

  • Activist Jana Partners pushes for sale and CEO change Activist investor Jana Partners sent a letter urging Cooper to pursue a sale, replace its CEO, and consider selling assets. The stock rose 1.7% after hours on the news, as investors saw a chance for a shake-up that could boost value after a 34% year-to-date decline.

    This is the latest new development that could change the company's direction and stock price.

© 2026 MarketDXWhy